<DOC>
	<DOCNO>NCT01193244</DOCNO>
	<brief_summary>This randomize , double-blind , multicenter , phase 3 study evaluate orteronel ( TAK-700 ) plus prednisone compare placebo plus prednisone treatment men progressive , chemotherapy-naive , metastatic , castration-resistant prostate cancer ( mCRPC )</brief_summary>
	<brief_title>Study Comparing Orteronel Plus Prednisone Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<criteria>Each patient must meet follow inclusion criterion : Voluntary write consent Male patient 18 year old Histologically cytologically confirm diagnosis prostate adenocarcinoma Radiographdocumented metastatic disease Progressive disease Prior surgical castration concurrent use agent medical castration Either absence pain pain require use opioid narcotic analgesia 2 week prior study entry Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Even surgically sterilize , patient must practice effective barrier contraception entire study treatment 4 month last dose study drug , OR abstain heterosexual intercourse Meet screen laboratory value specify protocol Stable medical condition Patients meet follow exclusion criterion enrol study : Known hypersensitivity orteronel , prednisone gonadotropinreleasing hormone ( GnRH ) analogue Received prior therapy orteronel , aminoglutethimide , ketoconazole abiraterone Received antiandrogen therapy within 6 week bicalutamide 4 week others prior first dose study drug Continuous daily use oral prednisone oral dexamethasone 14 day within 3 month prior study Received prior chemotherapy prostate cancer exception neoadjuvant/adjuvant therapy part initial primary treatment local disease complete 2 year prior screen Exposure radioisotope therapy within 4 week receive first dose study drug ; exposure external beam radiation within 2 week start screen receive first dose study drug Documented central nervous system metastases Treatment investigational compound within 30 day prior first dose study drug Current spinal cord compression , bilateral hydronephrosis current bladder neck outlet obstruction Diagnosis treatment another malignancy within 2 year precede first dose study drug except nonmelanoma skin cancer situ malignancy completely resect Uncontrolled cardiovascular condition specify study protocol Known history human immunodeficiency virus ( HIV ) infection , hepatitis B , hepatitis C Unwilling unable comply protocol Uncontrolled nausea , vomit diarrhea Known gastrointestinal disease procedure could interfere oral absorption tolerance orteronel</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>